Qualitätsbericht 2010 - im Klinikum Oldenburg

Onkologie/Hämatologie
12. HD16
13. HD18
14. MC-FLUDT Phase III Treosulfan-based conditioning vs. RIC
15. ML 22371 (Convince)
16. Breast Cancer in Pregnancy
17. "GEPARquinto" Neoadj. Behandlung des primär unbehandelten Mamma- CA
18. IBIS II DCIS Tamoxifen versus Anastrozol bei postmenop. Frauen mit DCIS
19. IBIS II Prevention
20. MINDACT-EORTC 10041/BIG 3-04
21. Placebo vs. Neratinib (HKI-272) After Trastuzumab in Early-Stage HER-2/neu pos.
Bre
22. TABEA: Taxane and bevacizumab with or +/- capecitabine as first line
chemotherapy in
23. Trio 12
24. DSMM XIII
25. MINT-FU
26. DSGL 01/2003
27. PTLD-1
28. AATT
29. DSHNHL 2002-1 (Mega-CHOEP Phase III)
30. DSHNHL 2006-1B/ACT-2
31. FLYER 6-6/6-4-Studie - DSHNHL 2004-2
32. MCL younger
33. NHL-ZNS-Rezidive
34. UNFOLDER 21/14 - DSHNHL 2004-3
35. AGO-OVAR 12
36. C-II-004 gemcitabine plus sunitinib vs gemcitabine alone in first-line therapy of
metastat
37. OSAG 101 Gemcitabine+Nimotuzumab vs. Gemcitabine+Placebo for patients with
adv.
38. Ewing 2008
39. PACET-CUP